Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of September 16, 2024
Click Here to Manage Email Alerts
In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.
Read the full coverage here:
FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy
Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’
Perioperative nivolumab improves outcomes in resectable NSCLC
Despite progress, barriers to lung cancer biomarker testing persist
Atezolizumab regimen ‘merits further study’ for unresectable NSCLC
References:
Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.
Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.
Collapse
Read more about
Click Here to Manage Email Alerts
